This website is intended for UK healthcare professionals.
The Adverse Event Reporting and a link to the Prescribing Information can be found at the bottom of the page.

Equasym XL logo

Equasym® XL (methylphenidate hydrochloride modified release capsules) is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient.1

Treatment must be under the supervision of a specialist in childhood behavioural disorders.1

Request a call from a Takeda representative to discuss Equasym XL

Icon

View the Equasym XL patient booklet

Icon

A booklet for child & adolescent patients who have been prescribed Equasym XL explaining what the medication is, what they can expect from it, and how it should be taken.

References

  1. Equasym XL. Summary of Product Characteristics.